Nyxoah implants first U.S. commercial patients with Genio system

Nyxoah (NYXH) announced that the first U.S. commercial patients have been successfully implanted with the Genio system following FDA approval. “We are thrilled to announce that the first commercial patients have now received Genio implants, marking a significant milestone in bringing this innovative therapy to OSA patients in the U.S.,” said Olivier Taelman, CEO. “Importantly, we have trained surgeons, obtained Value Analysis Committee (VAC) approvals and achieved successful coverage from major payors including CMS. What’s also particularly encouraging is the strong demand we’re seeing from physicians, with surgeons actively reaching out for training opportunities, many of whom already have patients lined up for implants. These early leading indicators give us confidence that we’re building the right foundation for the sustained adoption of Genio moving forward.”